2003
American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting.
Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. Journal Of Clinical Oncology 2003, 21: 2597-9. PMID: 12732612, DOI: 10.1200/jco.2003.04.596.Peer-Reviewed Original Research
1999
Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support
Winer E, Lindley C, Hardee M, Sawyer W, Brunatti C, Borstelmann N, Peters W. Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support. Psycho-Oncology 1999, 8: 167-176. PMID: 10335560, DOI: 10.1002/(sici)1099-1611(199903/04)8:2<167::aid-pon354>3.0.co;2-s.Peer-Reviewed Original ResearchConceptsFunctional Living Index-CancerHigh-dose chemotherapyQuality of lifeAutologous bone marrow supportBone marrow supportSymptom Distress ScaleDose chemotherapyBreast cancerMarrow supportSexual functioningMajority of patientsBreast cancer patientsLong-term outcomesTreatment of patientsMore yearsFLIC scoresTransplant supportIndex cancerRecurrent diseaseAssessment of qualityMedian timeCancer patientsSexual functionClinical trialsSevere symptoms